GlassScriptPhysician profile
Anthony H Jung
NPI 1144340225
$7,544.09
in general payments reported to CMS, 2019-2025
22 companies · $1,327 in 2025
The $1,327 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,180 · 2020: $767 · 2021: $1,035 · 2022: $984 · 2023: $1,198 · 2024: $1,052 · 2025: $1,327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,449 · Education: $129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,448.68 |
| Education | $129.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,114.07 | 2019-2025 | Evenity, Repatha, Tepezza |
| Gilead Sciences, INC. | $854.43 | 2019-2024 | Vemlidy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $812.28 | 2019-2024 | Jardiance, Synjardy |
| Astrazeneca Pharmaceuticals LP | $809.13 | 2020-2023 | Calquence, Tagrisso, Farxiga |
| Novo Nordisk INC | $515.25 | 2021-2025 | Ozempic, Rybelsus |
| Nestle Healthcare Nutrition INC. | $375.00 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $368.50 | 2023-2025 | |
| Ardelyx, INC. | $245.46 | 2022-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $243.16 | 2024-2025 | Voquezna |
| Amarin Pharma, INC. | $242.73 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $170.15 | 2024 | |
| Allergan, INC. | $137.37 | 2019 | |
| Sumitomo Pharma America, INC. | $125.00 | 2023 | Gemtesa |
| Exact Sciences Corporation | $119.81 | 2025 | Cologuard Collection Kit |
| Abbvie INC. | $114.49 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $81.95 | 2019 | |
| Insmed, INC. | $81.68 | 2019 | |
| Mannkind Corporation | $42.50 | 2025 | |
| Medtronic, INC. | $29.62 | 2025 | Minimed 780g |
| Teva Pharmaceuticals USA, INC. | $23.22 | 2024 | Uzedy |
| Medtronic Minimed, INC. | $20.98 | 2019 | |
| Tersera Therapeutics LLC | $17.31 | 2024 | Zoladex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Jung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.